Yes, there are ongoing clinical trials studying trametinib for colorectal cancer. Trametinib is a medication that belongs to a class of drugs called MEK inhibitors, which are used to treat certain types of cancer. These trials aim to evaluate the safety and effectiveness of trametinib in treating colorectal cancer patients.

One source, DrugPatentWatch, provides information on the patent status of trametinib, indicating that it is an approved drug used for the treatment of various cancers, including colorectal cancer [1].

Another source, the National Cancer Institute's clinical trials database, lists a clinical trial with the identifier NCI-2017-00868, which is studying trametinib in combination with other drugs for the treatment of colorectal cancer [2].

Additionally, a search on ClinicalTrials.gov using the identifier NCT03087071 reveals an ongoing clinical trial investigating the efficacy and safety of trametinib in combination with another drug for patients with metastatic colorectal cancer [3].

These sources confirm that there are ongoing clinical trials studying the use of trametinib for colorectal cancer treatment. However, it is important to note that the results of these trials are not yet available, and further research is needed to determine the full potential of trametinib in treating colorectal cancer.

Sources:
[1] DrugPatentWatch. Trametinib. Retrieved from https://www.drugpatentwatch.com/p/tradename/TRAMETINIB
[2] National Cancer Institute. Clinical Trials Search Results: NCI-2017-00868. Retrieved from https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2017-00868
[3] ClinicalTrials.gov. Study of Trametinib and TAS-102 in Patients With Advanced Colorectal Cancer Refractory to Standard Therapies. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03087071